EUCTR2018-003249-41-BE进行中（未招募）1 期
A multicentre phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER-2 negative breast cancer, suitable for treatment with a taxane - M18DMB
Modra Pharmaceuticals B.V.0 个研究点目标入组 24 人开始时间: 2018年9月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Able to give written informed consent and to comply with the protocol
- •2.Histologically- or cytologically confirmed diagnosis of recurrent or metastatic HER-2 negative breast cancer
- •3.Female of age 18 years or above
- •4.Patients who are eligible to receive a taxane as monotherapy as 1st-3rd line of therapy for recurrent or metastatic breast cancer. A maximum of two previous lines of chemotherapy is allowed (including experimental i.e. non-registered chemotherapy alone or in combination). Re-treatment with one of the same drugs after treatment interruption for reasons of patient preference and/or progression of disease counts as a new treatment
- •5.WHO performance status of 0, 1 or 2 (Appendix II)
- •6.Estimated life expectancy of at least 12 weeks
- •7.Resolution of toxicity of prior therapy to < grade 2 (except for alopecia and transaminases in case of liver metastases) as defined by CTCAE v5.0
- •8.Evidence of measurable disease present at baseline as defined by RECIST v1.1
- •9.Able and willing to swallow oral medication
- •10.Able and willing to undergo radiologic scans (CT scan, or MRI if CT is contraindicated)
- •11.All patients of childbearing potential must have a negative high sensitive pregnancy test at screening (urine/serum) and agree to use highly effective method for contraception from time of signing Informed Consent until at least 12 weeks after the last administration of study drug
- •12.Laboratory criteria:
- •Platelet count = 100 x 109 /L
- •Haemoglobin = 6.0 mmol/L or 9.67 g/dL
- •Absolute Neutrophil Count (ANC) = 1.5 x 109 /L
- •Total bilirubin = 1.5 x ULN, except for patients with familial bilirubinaemia (Gilbert’s disease)
- •Serum ASAT and ALAT = 2.5 x ULN (= 5 x ULN with liver metastases)
- •Serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min (by Cockcroft-Gault formula or MDRD [Modification of Diet in Renal Disease])
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1.Systemic chemotherapy and radiation therapy within the last 4 weeks, endocrine based therapy and CDK4/6 inhibitors within 1 week prior to first dose of ModraDoc006/r. Single dose palliative radiation for pain relieve is allowed until one week prior to start with ModraDoc006/r (these lesions are not to be included as target lesions)
- •2.Any treatment with investigational drugs (or investigational device) within 21 days prior to receiving the first dose of ModraDoc006/r
- •3.Previous treatment with a taxane for recurrent or metastatic breast cancer
- •4.Major surgical procedures within 21 days prior to providing informed consent
- •5.Active acute or chronic infection, which is not controlled by appropriate medication (at the discretion of the treating physician)
- •6.Uncontrolled or significant cardiovascular disease defined as New York Heart Association Classification III or IV
- •7.Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the Investigator would impair study compliance
- •8.Any medical condition that in the opinion of the Investigator would contra-indicate or preclude participation within the clinical trial, or would put the patient at high risk for treatment-related complications
- •9.Previous malignancies within the last three years other than breast carcinoma, except successfully treated squamous/basal cell carcinoma of the skin, superficial bladder cancer, and in situ carcinoma of the cervix
- •10.Patients with symptomatic brain metastases. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy for at least 6 weeks are allowed to enrol. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening, demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive anti-epileptic drugs or corticosteroid treatment indicated for brain metastasis
- •11.Patients with confirmed leptomeningeal metastases
- •12.Women who are pregnant or breast feeding
- •13.Known positivity for Human Immunodeficiency Virus HIV-1 or HIV-2 type
- •14.Patients with known active infection of hepatitis B, C, or E (patients who are anti-HBC positive but HBsAg negative are eligible to participate in this study)
- •15.Bowel obstructions or motility disorders that may influence the resorption of drugs as judged by the Investigator
- •16.Patients with unstable ascites, defined as need for palliative paracentesis or presence of a permanent peritoneal drain in the past 4 weeks prior to first dose of ModraDoc006/r. Enrolment in patients with peritonitis carcinomatosa and malignant ascites is allowed if there is no clinical and/or radiological known or suspected motility disorder within the 4 weeks prior to the first dose of ModraDoc006/r
- •17.Concomitant use of MDR, MRP, OATP1B1, OATP1B3 and CYP3A modulating drugs such as Ca+- entry blockers (verapamil, dihydropyridines), cyclosporine, quinidine, tamoxifen, megestrol and grapefruit juice, concomitant use of HIV medications, other protease inhibitors, (non) nucleoside analogues, or St. John’s wort (see section 5.8). These need to have been stopped at least 5 times half-life (according to Summary of Product Characteristics (SPC)) or 7 days, whichever is longest, in order to prevent interactio
研究者
相似试验
进行中（未招募）
1 期
A study in HER-2 negative metastatic breast cancer patients receiving ModraDoc006/r, an oral chemotherapy treatment regime of docetaxelrecurrent/ metastatic HER-2 negative breast cancer, suitable for treatment with a taxaneMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003249-41-DKModra Pharmaceuticals B.V.24
进行中（未招募）
1 期
A study in HER-2 negative metastatic breast cancer patients receiving ModraDoc006/r, an oral chemotherapy treatment regime of docetaxelrecurrent/ metastatic HER-2 negative breast cancer, suitable for treatment with a taxaneMedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003249-41-ESModra Pharmaceuticals B.V.24
进行中（未招募）
2 期
DexICE therapy for refractory LBNon-Hodgkin lymphomaJPRN-jRCTs041180184Mitsui Tetsuo24
进行中（未招募）
1 期
A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine incorporating the prospective validation of molecular classifiers and exploratory metabonomics. - CUP ONEMetastatic Carcinomas of Unknown Primary origin (CUP)EUCTR2008-000657-35-GBGreater Glasgow and Clyde Health Board (GGCHB)/University of Glasgow59
进行中（未招募）
不适用
A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer - Monica StudyEUCTR2005-000074-51-DEGBG Forschungs GmbH